Compass Pathways plc

Clinical-stage mental health company developing COMP360, a proprietary synthetic psilocybin, for treatment-resistant depression and PTSD. The company reported positive Phase 3 6-week data from the COMP005 pivotal trial in TRD and is preparing a rolling NDA submission, with commercial launch readiness targeted by end of 2026.